Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Omega-3 Under Scrutiny: Pure C15:0 Emerges as Safer and More Effective Alternative


News provided by

Seraphina Therapeutics

Sep 28, 2023, 11:00 ET

Share this article

Share toX

Share this article

Share toX

Recent Scientific Study Sparks Concerns of Omega-3 Efficacy, as Pure C15:0 Emerges as Better, Broader, and Safer

SAN DIEGO, Sept. 28, 2023 /PRNewswire-PRWeb/ -- A recent scientific study (Journal of Dietary Supplements) revealing concerns about levels of rancidity in conventional omega-3 fish oil supplements has sent shockwaves through the wellness industry. In response, Seraphina Therapeutics and its innovative product, fatty15, have stepped into the spotlight as a pure, quality, and vegan solution that not only avoids the pitfalls associated with fish oil but also outperforms omega-3 supplements threefold.

The study, published in the Journal of Dietary Supplements, examined a range of commercially available omega-3 supplements and found that a significant number of them had elevated levels of rancidity, which can compromise both the safety and effectiveness of these products. These findings are consistent with prior peer reviewed studies about omega-3 supplements, which are raising serious questions about the quality of omega-3 supplements commonly found on store shelves.

Compromised quality of omega-3 supplements may also explain why the National Institutes of Health concludes, "Research indicates that omega-3 supplements don't reduce the risk of heart disease…and for most other conditions for which omega-3 supplements have been studied, the evidence is inconclusive or doesn't indicate that omega-3s are beneficial."

While the science behind omega-3s has been falling, voluminous science behind C15:0 (pentadecanoic acid) has been building. Thanks to a surprising discovery of C15:0's health benefits, made while helping to protect the health of older Navy dolphins, it now appears that omega-3s may have been a red herring for which fatty acids are actually the most beneficial in fish.

As a veterinary epidemiologist working for the Navy Marine Mammal Program, Dr. Stephanie Venn-Watson led a study to determine which fatty acids in fish were predictive of the healthiest aging dolphins. Instead of omega-3s, higher levels of odd-chain saturated fatty acids (including C15:0) predicted the healthiest dolphins. Dr. Venn-Watson and her Navy physician husband, Dr. Eric Venn-Watson, co-founded Seraphina Therapeutics to advance C15:0 studies and bring C15:0 to the world as a healthier, safer, and more effective alternative than omega-3 supplements.

Fatty15, developed by Seraphina Therapeutics in cooperation with the U.S. Navy, represents a breakthrough in the way we treat our overall health and wellness at the cellular level. Fatty15 is a pure, patented, and vegan-friendly powder that harnesses the power of C15:0, the first essential fatty acid to be discovered in over 90 years. Recent research has demonstrated that the pure C15:0 in fatty15 is 3x more effective than even pure omega-3 (eicosapentaenoic acid) in repairing and protecting cells.

Fatty15 sets the gold standard for purity as the world's only > 99% pure plant-based, award-winning, and science-backed C15:0 supplement. Unlike omega-3 oil supplements, fatty15 is a stable powder that does not oxidize and is not susceptible to rancidity. Developed by Seraphina's team of doctors and scientists, in collaboration with its team of esteemed scientific advisors, fatty15 adheres to the strictest standards, including FDA regulations, Good Manufacturing Practices (cGMPs), and Generally Recognized As Safe (GRAS) status. This unwavering commitment ensures a product that meets the highest quality, efficacy and safety benchmarks.

Fatty15 is the result of years of rigorous research. A recent peer-reviewed study compared fatty15 head-to-head against the purest, highest performing omega-3 (EPA). Fatty15 had 36+ clinically relevant cellular benefits across 83% of cell types tested, which was 3x better than omega-3. While omega-3 was toxic to cells at the highest doses, fatty15 was safe at all levels.

"The recent study shedding light on the rancidity problem in fish oil supplements underscores the critical necessity for a safer and more reliable alternative. Fatty15 not only addresses this need but also eclipses traditional EPA omega-3 supplements, proving to be 3x more effective in protecting our cells," stated Dr. Eric Venn-Watson, Co-Founder of Seraphina Therapeutics.

In a rapidly evolving health and wellness landscape, Seraphina Therapeutics and fatty15 remain at the forefront of innovation, committed to offering science-backed solutions that consumers can trust.

About Seraphina Therapeutics. Inc.:
Seraphina Therapeutics, Inc. is a health and wellness company dedicated to advancing global health through the discovery of essential fatty acids and micronutrient therapeutics. Through rigorous breakthrough science, the company develops fatty acid supplements, food fortifiers, and nutritional interventions to strengthen cells, keep mitochondria working and advance cellular homeostasis to counter age-related breakdown. With its team of industry-leading scientists, Seraphina Therapeutics challenges long-held approaches to nutrition, enabling the creation of novel health products designed to support quality of life. For more information, please visit DiscoverC15.com and fatty15.com.

Media Contact

GR0 Agency, GR0, (310) 439-1887, [email protected], gr0.com

SOURCE Seraphina Therapeutics

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.